Condition
ANCA Associated Systemic Vasculitis
Total Trials
5
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Recruiting3
Enrolling By Invitation1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07507201Early Phase 1Recruiting
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
NCT07413341Phase 1Recruiting
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
NCT07305116Phase 1Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT05859997Not ApplicableEnrolling By Invitation
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT00430105Phase 2CompletedPrimary
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
Showing all 5 trials